Life Sciences
Risk & Life Sciences
Sustainable growth relies on an ability to balance myriad risks. This is done with partners through R&D [Research & Development] cooperation & marketing alliances or with financial engineering through mergers, spin-offs and acquisitions. Risk can be mitigated through good communication, project-portfolio management and human resource development. In an age of globalisation, short product cycles, close public scrutiny and intense competitive pressure, what strategies are available for the Life Science sector to balance concurrent risk throughout the global value chain while pursuing growth opportunities?
Session 1, May 3, afternoon
Leif Edvinsson, CEO, Universal Networking Intellectual Capital
Linking intellectual capital, organizational dynamics and the management of risk
The life sciences are undergoing structural changes in terms of their use of intellectual property, the location of research activities and clinical trials, in terms of their relationship with the public and with public authorities as well the outsourcing of significant parts of the innovation process. What is driving these changes? Are concepts and measures of 'value' changing in the life sciences? How do organizational dynamics affect stocks of intellectual capital? How will this influence the management of human and intellectual capital? What are the major risks that large life-science companies will face over the next 10 years?
Industrial eco-systems for success in the life sciences
The development of new life science based business is very risky. So how is the game changing from a researcher's point of view, from an entrepreneur's point of view and from an investor's point of view? What are the big opportunities for life science based start-ups? What are the major risks that entrepreneurs will face? What new thinking is emerging about how to handle it? What kind of a business eco-system for start-up and survival? What role will life-science majors and the public sector play in the new environment of risk?
Session 2, May 4, morning
The merits of starting small
The future of life science is small and specialized! So how do small companies cope with long-development times and high risk of new product development for the life sciences? What role is played by intellectual property? How can they maintain an adequate patent pipeline and how what do they do once the patents run out? How do small life-science companies attract and retain high quality employees? Are they a good career alternative for the best graduates? How will the role of major life-science company's change and what will the industry look like in 20 years time?
21st Century Bio-Technology: Novel perspectives on scope, risks and rewards
Successful navigation of the biotech opportunity space requires a good map of the relative risk / reward profiles of distinct segments along its value chain. How does the current landscape of modern biotech industry look like? Which market segments yield the highest rewards? Which technologies possess the highest potential? Which activities offer superior positioning? Which applications have balanced risk profiles? And how will this current topology unfold into the foreseeable future?
Catalysts
Trend Watcher
University Partners
Philosophers
Psychologist
Knowledge Stream Leader
